JP2021024810A - 経粘膜投与薬剤 - Google Patents
経粘膜投与薬剤 Download PDFInfo
- Publication number
- JP2021024810A JP2021024810A JP2019143948A JP2019143948A JP2021024810A JP 2021024810 A JP2021024810 A JP 2021024810A JP 2019143948 A JP2019143948 A JP 2019143948A JP 2019143948 A JP2019143948 A JP 2019143948A JP 2021024810 A JP2021024810 A JP 2021024810A
- Authority
- JP
- Japan
- Prior art keywords
- podocalyxin
- drug
- antibody
- transmucosal administration
- target molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
Abstract
Description
1)ポドカリキシン標的分子を結合させた薬剤化合物を有効成分とする経粘膜投与薬剤。
2)ポドカリキシン標的分子を結合させた薬剤化合物を含有する経粘膜投与組成物。
3)ポドカリキシン標的分子が抗ポドカリキシ抗体又はその抗原結合断片である、1)の経粘膜投与薬剤。
4)ポドカリキシン標的分子が抗ポドカリキシ抗体又はその抗原結合断片である、2)の経粘膜投与組成物。
5)組成物が経鼻吸入、経肺吸入、気管若しくは気管支吸入、又は点眼のための組成物である、2)又は4)の経粘膜投与組成物。
本発明におけるポドカリキシン標的分子とは、ポドカリキシンと結合する能力、好ましくは特異的に結合する能力を有する分子を意味する。標的分子の化学種は特に制限されず、低分子化合物、高分子化合物、生体由来物質等様々な化学種を含むことができる。具体的には、例えば糖類、脂質類、オリゴペプチド、タンパク質、及び核酸を挙げることができる。標的分子の機能としては、例えばポドカリキシンを認識する抗体、レクチン、相互作用タンパク質等を挙げることができる。ポドカリキシン標的分子としては、好ましくは、抗ポドカリキシ抗体又はその抗原結合断片、レクチン(例えば、rBC2LCN)等が挙げられる。
抗ポドカリキシ抗体の抗原結合断片とは、抗ポドカリキシン抗体の断片(フラグメント)であって、ポドカリキシンに結合する断片を意味する。具体的には、VL、VH、CL、及びCH1領域からなるFab、2つのFabがヒンジ領域でジスルフィド結合によって連結されているF(ab)2、VL及びVHからなるFv、VL及びVHを人工のポリペプチドリンカーで連結した一本鎖抗体であるscFvの他、diabody型、scDb型、tandemscFv型、ロイシンジッパー型等の二重特異性抗体等が挙げられる。
したがって、ポドカリキシン標的分子を結合させた薬剤化合物は経粘膜投与薬剤となり得る。
当該組成物の剤形としては、各種の体腔等の粘膜上で溶解又は崩壊できるものであれば、特に限定されず、投与部位となる部位に倣った形状等とすることができる。すなわち、フィルム、タブレット、乾燥粉末の他、チューブ等の容器やカプセル等に充填され得る液剤(懸濁状、不定形ゲル状を含む)等とすることができる。
例えば、呼吸器(例えば鼻)の粘膜への送達を意図したものである場合、典型的は、組成物は、エアロゾル又は点鼻薬としての投与のために水性溶液として製剤されるか、あるいは、例えば鼻道内で迅速に堆積するように乾燥粉末として製剤化される。
液剤としては、精製水、緩衝液に溶解したもの等が挙げられる。懸濁剤としては、メチルセルロース、ヒドロキシメチルセルロース、ポリビニルビロリドン、ゼラチン、カゼイン等と共に精製水、緩衝液等に懸濁させたもの等が挙げられる。
また、フィルム状製剤やタブレット状製剤としては、水溶性マトリックス材料(例えば、プルラン、ポリビニルアルコール(PVA)、ヒドロキシプロピルセルロース(HPC)、ポリビニルピロリドン(PVP)、ゼラチン、デンプン等)からなり、粘膜付着層を含む積層構造を有する成形体が挙げられる。
なお、乾燥粉末製剤には、粘膜接着性物質の他、充填剤や適切な粉末流及びサイズの特徴を齎すための作用物質(例えばマンニトール、ショ糖、トレハロース、キシリトール等)を適宜配合することができる。
参考例1 in vitro M−like cellにおけるポドカリキシンの発現確認
文献(Kai H, Motomura Y, Saito S, Hashimoto K, Tatefuji T, Takamune N, Misumi S.Royal jelly enhances antigen-specific mucosal IgA response. Food Sci Nutr. 2013 Mar 6;1(3):222-227.)に記載の通り、トランズウェル(Corning、ポアサイズ:3μm、24ウェル)の膜上に3×105個のCaco−2細胞を播種し、一晩静置して、その後20%仔ウシ血清、0.1mM 非必須アミノ酸を含むイーグルスMEM(20%FBS、0.1mM NEAA EMEM)を加えた24ウェルプレートにトランズウェルの膜を浸漬させる。おおよそ3日ごとに新たな20%FBS、0.1mM NEAA EMEMを加えた24ウェルプレートにトランズウェルを移し替えながら、21日間培養し、Caco−2の単層を形成させる。21日間の培養後、トランズウェルの上部チャンバーに1×106個のRaji B細胞を加え、更に3日間培養することでM−like cellへの分化を促した。このとき、対照としてRaji B細胞と共培養しないトランズウェルも作製した(対照:Caco−2単層)。
カニクイザルの盲腸から回腸側へ30cmの所から盲腸までの部分を切除し、これをOCT Compound(サクラファインテック)で埋包して凍結切片を作製した。パイエル板を含む凍結切片を冷アセトンに浸漬して固定化処理を行い、その後5%スキムミルク含有D−PBSに3時間浸してマスキング処理を行った。マスキング後、抗ポドカリキシン抗体(R&D Systems)、Alexa488標識したロバ抗ヤギIgG抗体、Alexa555標識した抗GP2抗体、及びジアミノ−フェニルイオダイド(DAPI)を含むスキムミルク含有D−PBSで染色を行った。染色後の組織切片をレーザー顕微鏡(Keyence)で観察した。
ビオチン標識ヤギ抗マウスIgG抗体(Jackson ImmunoResearch)をビオチンとして220pmol採取し、そこへ950μLのPBSを加え、更に0.1mg相当のFluoSpheresTM Streptavidin−Labeled Microspheresを少しずつ添加した。添加後、遮光して1時間振とうし、抗マウスIgG抗体が結合した蛍光ビーズを調製した。
Claims (5)
- ポドカリキシン標的分子を結合させた薬剤化合物を有効成分とする経粘膜投与薬剤。
- ポドカリキシン標的分子を結合させた薬剤化合物を含有する経粘膜投与組成物。
- ポドカリキシン標的分子が抗ポドカリキシ抗体又はその抗原結合断片である、請求項1記載の経粘膜投与薬剤。
- ポドカリキシン標的分子が抗ポドカリキシ抗体又はその抗原結合断片である、請求項2記載の経粘膜投与組成物。
- 組成物が経鼻吸入、経肺吸入、気管若しくは気管支吸入、又は点眼のための組成物である、請求項2又は4記載の経粘膜投与組成物。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019143948A JP7355326B2 (ja) | 2019-08-05 | 2019-08-05 | 経粘膜投与薬剤 |
AU2020324765A AU2020324765A1 (en) | 2019-08-05 | 2020-08-04 | Pharmaceutical agent for transmucosal administration |
US17/632,785 US20220288224A1 (en) | 2019-08-05 | 2020-08-04 | Pharmaceutical agent for transmucosal administration |
PCT/JP2020/029836 WO2021025020A1 (ja) | 2019-08-05 | 2020-08-04 | 経粘膜投与薬剤 |
KR1020227004653A KR20220042374A (ko) | 2019-08-05 | 2020-08-04 | 경점막 투여 약제 |
CN202080056172.4A CN114206390A (zh) | 2019-08-05 | 2020-08-04 | 经粘膜给药药剂 |
EP20850280.7A EP4011393A4 (en) | 2019-08-05 | 2020-08-04 | PHARMACEUTICAL AGENT FOR TRANSMUCOSAL ADMINISTRATION |
TW109126488A TW202122109A (zh) | 2019-08-05 | 2020-08-05 | 經黏膜投予藥劑 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019143948A JP7355326B2 (ja) | 2019-08-05 | 2019-08-05 | 経粘膜投与薬剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021024810A true JP2021024810A (ja) | 2021-02-22 |
JP7355326B2 JP7355326B2 (ja) | 2023-10-03 |
Family
ID=74503879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019143948A Active JP7355326B2 (ja) | 2019-08-05 | 2019-08-05 | 経粘膜投与薬剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220288224A1 (ja) |
EP (1) | EP4011393A4 (ja) |
JP (1) | JP7355326B2 (ja) |
KR (1) | KR20220042374A (ja) |
CN (1) | CN114206390A (ja) |
AU (1) | AU2020324765A1 (ja) |
TW (1) | TW202122109A (ja) |
WO (1) | WO2021025020A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7489057B2 (ja) | 2020-03-24 | 2024-05-23 | デンカ株式会社 | 抗ポドカリキシン抗体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2869674A1 (en) * | 2012-06-08 | 2013-12-12 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
US20140273016A1 (en) * | 2013-03-14 | 2014-09-18 | William Michael Schopperle | Device and method for the detection and diagnosis of aggressive and metastatic cancer and cancer stem cells employing podocalyxin and tra biomarkers |
WO2015058301A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
WO2016129660A1 (ja) * | 2015-02-12 | 2016-08-18 | 国立大学法人東北大学 | がん細胞特異的抗ポドカリキシン抗体とその製造方法 |
CA3000742A1 (en) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
KR102564754B1 (ko) | 2016-03-14 | 2023-08-08 | 큐어메타 테라퓨틱스 엘엘씨 | 포도칼릭신 및 tra-관련된 항체, 생산 방법 및 항암 치료제로서의 용도 |
-
2019
- 2019-08-05 JP JP2019143948A patent/JP7355326B2/ja active Active
-
2020
- 2020-08-04 US US17/632,785 patent/US20220288224A1/en active Pending
- 2020-08-04 CN CN202080056172.4A patent/CN114206390A/zh active Pending
- 2020-08-04 AU AU2020324765A patent/AU2020324765A1/en active Pending
- 2020-08-04 KR KR1020227004653A patent/KR20220042374A/ko unknown
- 2020-08-04 WO PCT/JP2020/029836 patent/WO2021025020A1/ja unknown
- 2020-08-04 EP EP20850280.7A patent/EP4011393A4/en active Pending
- 2020-08-05 TW TW109126488A patent/TW202122109A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP4011393A1 (en) | 2022-06-15 |
WO2021025020A1 (ja) | 2021-02-11 |
KR20220042374A (ko) | 2022-04-05 |
JP7355326B2 (ja) | 2023-10-03 |
CN114206390A (zh) | 2022-03-18 |
US20220288224A1 (en) | 2022-09-15 |
EP4011393A4 (en) | 2022-11-30 |
TW202122109A (zh) | 2021-06-16 |
AU2020324765A1 (en) | 2022-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2081960B1 (en) | Intranasal delivery of polypeptides and proteins | |
CN105164143B (zh) | 用于将分子引入到乳糜微粒中的胆固醇体囊泡 | |
US7927622B1 (en) | Methods of transnasal transport/immunization with highly adaptable carriers | |
JPH04507106A (ja) | ヒドロキシアパタイト―抗原結合体及びポリ―ig免疫応答を生成する方法 | |
CN109152738A (zh) | 组合物 | |
MX2007000510A (es) | Composiciones para suministrar peptido yy y agonistas de pyy. | |
WO2021025020A1 (ja) | 経粘膜投与薬剤 | |
ES2282256T3 (es) | Anticuerpos policlonales recombinantes o purificados para tratar la alergia. | |
Klinguer et al. | Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens | |
WO2022023566A2 (en) | Cd-3 antibodies for the treatment of coronavirus | |
Watanabe et al. | Induction of antigen-specific IgA-forming cells in the middle ear mucosa | |
Lazorová et al. | Intestinal tissue distribution and epithelial transport of the oral immunogen LTB, the B subunit of E. coli heat-labile enterotoxin | |
CN101611060A (zh) | 鼻内递送肽和蛋白质 | |
JP2022505318A (ja) | 吸入用乾燥医薬組成物 | |
WO2018178594A1 (fr) | Prévention d'une infection par le virus respiratoire syncytial dans les voies respiratoires supérieures | |
CN112203640B (zh) | 抑制病原体感染的组合物和方法 | |
WO2023166206A1 (en) | Il-18 binding protein (il-18bp) in the treatment of vexas | |
EP4323411A1 (en) | Functionalized biological membranes with modifying protein molecules, and methods of making and uses thereof | |
KR100507449B1 (ko) | 흡착된 단백질과 항체를 갖는 미세입자를 포함하는 비강내 투여용 약제 조성물 | |
WO2004028561A1 (ja) | 免疫応答誘導方法 | |
JP2004292419A (ja) | 経口薬剤および成分の吸収改善剤 | |
WO2019121966A1 (fr) | Composition pharmaceutique pour administration orale d'anticorps pour le traitement des maladies du tractus gastro-intestinal | |
Morishita et al. | Biodrug Delivery Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20200609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200630 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220721 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230710 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230912 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7355326 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |